Back to cases

Diabetes · Diabetes mellitus

童某平· 50 male

Country
China
Treatment start
2023-09

Anamnesis

Tóng Mǒupíng, male, age 50, type 2 diabetes for 5+ years, on oral hypoglycemic therapy (metformin 2 tablets twice daily), postprandial blood glucose no lower than 12.0 mmol/L. Recent weight loss of ~5 kg, difficulty falling asleep, light sleep, frequent night-time waking.

Treatment plan

September 2023: perinatal NK immune cells 2U single dose + umbilical cord mesenchymal stem cells (UC-MSC) 6U IV ×3 administrations, monthly interval.

SchemaNK 2U ×1 + UC-MSC 6U ×3 monthly
Therapy
NK perinatalUC-MSC (umbilical cord MSC)
Delivery route
Intravenous (IV)

Outcome

After one course of stem cell therapy, serum insulin rose from 6.81 µIU/mL to 8.94 µIU/mL — indicating improved β-cell function. Oral hypoglycemic dose reduced to 1 tablet twice daily. Postprandial blood glucose stable within normal range, general status improved, body weight gain 2 kg, facial skin tone restored, increased work capacity, marked improvement in sleep quality.

Laboratory tests (before / after)

Insulin before treatment

TestResultUnitReference
Serum insulin6.81µIU/mL3.00-25.00
  • Summary: no abnormalities
  • Test date: 2023-09-27

Insulin after treatment

TestResultUnitReference
Serum insulin8.94µIU/mL2.2-25.00
  • Test date: 2023-12-27

Physician conclusion

Stem cell transplantation promotes regeneration of pancreatic islet β-cells, protects endogenous β-cells from apoptosis, improves insulin resistance, and lowers the risk of diabetes-related side effects.

Discuss your case

Share your diagnosis and history — the academic board responds within 24 hours with a preliminary assessment and protocol outline.

Get a consultation

We use cookies and analytics services to improve the website experience. Privacy Policy